随着诺和诺德、礼来业绩出炉,减肥药的“王者之争”暂时分出胜负。2024年,减肥用司美格鲁肽注射液Wegovy销售成绩超减重版替尔泊肽Zepbound,领先后者71.5%。绝对值来看,上市在后的Zepbound惜败,但据IQVIA数据,2024年的最后3个月内,在美国这个最大的市场,Wegovy每周处方总量已经输给礼来的减肥药Zepbound。凭借此前在“头对头”试验中获胜及专利到期时间更晚的优势,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.